je.st
news
Home
› ARCA Biopharma Announces IND Submission To US FDA For Gencaro For The Treatment Of Atrial Fibrillation
ARCA Biopharma Announces IND Submission To US FDA For Gencaro For The Treatment Of Atrial Fibrillation
2013-10-30 03:30:20| drugdiscoveryonline News Articles
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the GENETIC-AF clinical trial of Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF)
Tags: treatment
submission
ind
announces
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||